77 related articles for article (PubMed ID: 34752670)
1. Milvexian, an orally bioavailable, small-molecule, reversible, direct inhibitor of factor XIa: In vitro studies and in vivo evaluation in experimental thrombosis in rabbits.
Wong PC; Crain EJ; Bozarth JM; Wu Y; Dilger AK; Wexler RR; Ewing WR; Gordon D; Luettgen JM
J Thromb Haemost; 2022 Feb; 20(2):399-408. PubMed ID: 34752670
[TBL] [Abstract][Full Text] [Related]
2. Intravenously administered APAC, a dual AntiPlatelet AntiCoagulant, targets arterial injury site to inhibit platelet thrombus formation and tissue factor activity in mice.
Bonetti NR; Jouppila AS; Saeedi Saravi SS; Cooley BC; Pasterk L; Liberale LL; Gobbato S; Lüscher TF; Camici GG; Lassila RP; Beer JH
Thromb Res; 2023 Aug; 228():163-171. PubMed ID: 37331119
[TBL] [Abstract][Full Text] [Related]
3. A synthetic heparin mimetic that allosterically inhibits factor XIa and reduces thrombosis in vivo without enhanced risk of bleeding.
Al-Horani RA; Abdelfadiel EI; Afosah DK; Morla S; Sistla JC; Mohammed B; Martin EJ; Sakagami M; Brophy DF; Desai UR
J Thromb Haemost; 2019 Dec; 17(12):2110-2122. PubMed ID: 31397071
[TBL] [Abstract][Full Text] [Related]
4. Design, expression and biological evaluation of DX-88mut as a novel selective factor XIa inhibitor for antithrombosis.
Sun F; Wang W; Li Z; Li Y; Guo W; Kong Y
Bioorg Chem; 2024 Jan; 142():106951. PubMed ID: 37924755
[TBL] [Abstract][Full Text] [Related]
5. Incorporating Anticoagulant and Antiplatelet Dual Functional Groups into Thermosetting Polymer Chain for Enhancing Antithrombogenicity.
Wang W; Liu S; Zhang S; Zhang J; Tang Y; Zhang W
Adv Healthc Mater; 2023 Oct; 12(26):e2300680. PubMed ID: 37515824
[TBL] [Abstract][Full Text] [Related]
6. Dual Inhibition of Factor XIIa and Factor XIa Produces a Synergistic Anticoagulant Effect.
Jiang S; Li Y; Zhang J; Jia W; Zheng Y; Jia Z; Yu C; Kong Y
J Cardiovasc Pharmacol; 2024 Apr; ():. PubMed ID: 38922574
[TBL] [Abstract][Full Text] [Related]
7. Academia / Industry Collaborations towards the Functionalization of Aryl Azoles.
Wagschal S; Broggini D
Chimia (Aarau); 2024 Mar; 78(3):104-107. PubMed ID: 38547010
[TBL] [Abstract][Full Text] [Related]
8. Milvexian for the Prevention of Venous Thromboembolism.
Weitz JI; Strony J; Ageno W; Gailani D; Hylek EM; Lassen MR; Mahaffey KW; Notani RS; Roberts R; Segers A; Raskob GE;
N Engl J Med; 2021 Dec; 385(23):2161-2172. PubMed ID: 34780683
[TBL] [Abstract][Full Text] [Related]
9. Rationale and design of the AXIOMATIC-SSP phase II trial: Antithrombotic treatment with factor XIa inhibition to Optimize Management of Acute Thromboembolic events for Secondary Stroke Prevention.
Sharma M; Molina CA; Toyoda K; Bereczki D; Kasner SE; Lutsep HL; Tsivgoulis G; Ntaios G; Czlonkowska A; Shuaib A; Amarenco P; Endres M; Diener HC; Gailani D; Kahl A; Donovan M; Perera V; Li D; Hankey GJ
J Stroke Cerebrovasc Dis; 2022 Oct; 31(10):106742. PubMed ID: 36037679
[TBL] [Abstract][Full Text] [Related]
10. Factor XIa inhibition with asundexian after acute non-cardioembolic ischaemic stroke (PACIFIC-Stroke): an international, randomised, double-blind, placebo-controlled, phase 2b trial.
Shoamanesh A; Mundl H; Smith EE; Masjuan J; Milanov I; Hirano T; Agafina A; Campbell B; Caso V; Mas JL; Dong Q; Turcani P; Christensen H; Ferro JM; Veltkamp R; Mikulik R; De Marchis GM; Robinson T; Lemmens R; Stepien A; Greisenegger S; Roine R; Csiba L; Khatri P; Coutinho J; Lindgren AG; Demchuk AM; Colorado P; Kirsch B; Neumann C; Heenan L; Xu L; Connolly SJ; Hart RG;
Lancet; 2022 Sep; 400(10357):997-1007. PubMed ID: 36063821
[TBL] [Abstract][Full Text] [Related]
11. A Multicenter, Phase 2, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group, Dose-Finding Trial of the Oral Factor XIa Inhibitor Asundexian to Prevent Adverse Cardiovascular Outcomes After Acute Myocardial Infarction.
Rao SV; Kirsch B; Bhatt DL; Budaj A; Coppolecchia R; Eikelboom J; James SK; Jones WS; Merkely B; Keller L; Hermanides RS; Campo G; Ferreiro JL; Shibasaki T; Mundl H; Alexander JH;
Circulation; 2022 Oct; 146(16):1196-1206. PubMed ID: 36030390
[TBL] [Abstract][Full Text] [Related]
12. Safety, pharmacokinetics, and pharmacodynamics of milvexian in healthy Japanese participants.
Perera V; Wang Z; Lubin S; Ueno T; Shiozaki T; Chen W; Xu X; Seiffert D; DeSouza M; Murthy B
Sci Rep; 2022 Mar; 12(1):5165. PubMed ID: 35338177
[TBL] [Abstract][Full Text] [Related]
13. Single-Dose Pharmacokinetics of Milvexian in Participants with Mild or Moderate Hepatic Impairment Compared with Healthy Participants.
Perera V; Abelian G; Li D; Wang Z; Zhang L; Lubin S; Chen W; Bello A; Murthy B
Clin Pharmacokinet; 2022 Jun; 61(6):857-867. PubMed ID: 35262846
[TBL] [Abstract][Full Text] [Related]
14. Persistence Pays Off: Milvexian Emerges from the Industry's Longstanding Search for Orally Bioavailable Factor XIa Inhibitors.
Goodwin NC
J Med Chem; 2022 Feb; 65(3):1767-1769. PubMed ID: 34962399
[TBL] [Abstract][Full Text] [Related]
15. Fixed Drug Eruption Secondary to Four Anti-diabetic Medications: An Unusual Case of Polysensitivity.
Al Masri D; Fleifel M; Hirbli K
Cureus; 2021 Oct; 13(10):e18599. PubMed ID: 34786218
[TBL] [Abstract][Full Text] [Related]
16. Factor XI: structure, function and therapeutic inhibition.
Ali AE; Becker RC
J Thromb Thrombolysis; 2024 Apr; ():. PubMed ID: 38622277
[TBL] [Abstract][Full Text] [Related]
17. Cutting-Edge Techniques and Drugs for the Treatment of Pulmonary Embolism: Current Knowledge and Future Perspectives.
Falsetti L; Guerrieri E; Zaccone V; Viticchi G; Santini S; Giovenali L; Lagonigro G; Carletti S; Gialluca Palma LE; Tarquinio N; Moroncini G
J Clin Med; 2024 Mar; 13(7):. PubMed ID: 38610717
[TBL] [Abstract][Full Text] [Related]
18. Design and Preclinical Characterization Program toward Asundexian (BAY 2433334), an Oral Factor XIa Inhibitor for the Prevention and Treatment of Thromboembolic Disorders.
Roehrig S; Ackerstaff J; Jiménez Núñez E; Teller H; Ellerbrock P; Meier K; Heitmeier S; Tersteegen A; Stampfuss J; Lang D; Schlemmer KH; Schaefer M; Gericke KM; Kinzel T; Meibom D; Schmidt M; Gerdes C; Follmann M; Hillisch A
J Med Chem; 2023 Sep; 66(17):12203-12224. PubMed ID: 37669040
[TBL] [Abstract][Full Text] [Related]
19. Determination of the Potential Clinical Benefits of Small Molecule Factor XIa Inhibitors in Arterial Thrombosis.
Wichaiyo S; Parichatikanond W; Visansirikul S; Saengklub N; Rattanavipanon W
ACS Pharmacol Transl Sci; 2023 Jul; 6(7):970-981. PubMed ID: 37470020
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
